News | May 31, 2012

Occlutech Wins European Supreme Court Ruling on Cardiac Occluder Technology

May 31, 2012 Occlutech GmbH, a European developer of minimally invasive implants for the treatment of structural heart disease, announced receiving a favorable Supreme Court ruling from The Hague in The Netherlands in the ongoing patent litigation with AGA/St. Jude Medical. A first instance court ruling obtained in favour of Occlutech had been appealed by AGA in 2008, as had the favorable appeal court decision obtained in 2010.

In this final ruling, the Supreme Court saw no reason to change the favorable first instance and appeal court rulings. The Dutch Supreme court decision comes after Supreme Courts in Germany and the U.K. have decided in Occlutech's favour in the same matter and can't be appealed. Litigation in the same matter is ongoing in Italy, Sweden and Spain where Occlutech has won in the first instances.

"It is really sad to see the extent to which this large competitor is willing to go in order to try to keep a company with better technology off the market," said Tor Peters, Occlutech's CEO. "It is hard on Occlutech and our employees but the real losers are physicians and especially patients who have been denied superior products due to the aggressive litigation by AGA/St Jude Medical. We are dedicated not to give in to this kind of bullying and to continue to innovate, bringing superior products to the market."

Occlutech's own patent position has been continuously strengthened and a full pipeline of new technologies and products is being developed. Occlutech plans to launch additional occluder devices for indications such as PDA and VSD, in addition to second generation ASD and PFO occluders. In addition, an innovative LAA occluder, a new generation of stent grafts and cardiac valve intervention technology are also being developed.

For more information:

Related Content

Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Dee Dee Wang, Henry Ford Hospital, 3D printing for cardiology, 3-D

Dr. Dee Dee Wang with part of Henry Ford Hospital's collection of 3-D printed hearts used for education and to preplan structural heart procedures.

Feature | 3-D Printing| March 03, 2017
March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA) occlusion
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders| February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care
News | Cath Lab| January 23, 2017
January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended thr
Overlay Init